- Home
- PVLA vs IMTX Comparison
PVLA vs IMTX Comparison
Compare PVLA & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PVLA | IMTX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | Germany |
| Employees | 14 | 407 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PVLA | IMTX |
|---|---|---|
| Price | $117.76 | $11.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $171.87 | $19.00 |
| AVG Volume (30 Days) | 175.2K | ★ 489.7K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $104,350.18 | $25.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.20 | $5.05 |
| 52 Week High | $151.18 | $12.41 |
Technical Indicators
Market Signals| Indicator | PVLA | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 53.38 |
| Support Level | $109.68 | $9.05 |
| Resistance Level | $135.23 | $11.54 |
| Average True Range (ATR) | 5.65 | 0.57 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 58.97 | 64.77 |
Price Performance
Historical ComparisonAbout PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.